by Dr. Diana Rangaves, PharmD, RPh
There is so much noise surrounding Cannabis, it is close to impossible to separate fact from fiction. Everyone appears to want a piece of the hundred-billion dollar industry and turn a quick profit. Where can customers place trust and faith?
Sometimes the medical model does not work for us. We must take it upon ourselves to become seekers and information gathers. It takes work. This is where credible, cited and evidence-based science comes in to help us.
We can only make our best choices for our health with accurate information, minus the hype and sensationalism of a flash-pan headline. The science and future of CBD and CBDV is real. You judge the evidence.
Cannabidivarin (CBDV) is a non-psychoactive cannabinoid found in Cannabis Sativa, a plant known for its mind-altering qualities. Developments in the active CBDV research appear to support the use of helping those who suffer from seizures, helping with nausea, bone healing and possibly autism.
The key differences are that this derivative is not used for recreation or performance-enhancing effects. Cannabidivarin does not change the cannabinoid brain chemistry in the context of mood, cognition, or behavior change.
What is CBDV and its Relationship to Cannabis?
Scientists have been actively studying cannabis and health for decades.
Vollner made the very first isolation of cannabidivarin from Cannabis by in 1969. A few years later in 1972, Fetterman and Turner found that Indian varieties of the plant Cannabis Sativa contained two additional compounds. Another plant from Mexico had insignificant amounts of the two compounds identified as CBDV and THCV. This discovery took place at Mississippi University. In 2004, Hillig confirmed the Fetterman and Turner finding and reported that CBDV of Cannabis all derived from the Cannabis Indica plant.
Since CBDV can be separated from the Indica Cannabis Sativa plant, it will give a non-psychoactive effect to those ingesting the compound. In other words, CBDV provides relief without the worry of causing a high.
Benefits of CBDV in Epilepsy
In 2012, Hill reported another major finding. He discovered that CBDV has the potential to be useful as an anti-seizure agent. Hill reported that when testing with rats that CBDV exhibits strong and significant anticonvulsant effects.
Pentylenetetrazol (PTZ) is a substance that has seizure-inducing properties. It is used to study epilepsy in the identification of pharmaceuticals that can control the susceptibility and spread of seizures. PTZ is a central nervous system (CNS) stimulant. Not only was the PTZ seizures reduced, so too was the onset when CBDV was applied. Therefore, the findings revealed that CBDV reduces the incidence of convulsions or seizures from occurring in rats.
In 2016, Morano wished to broaden the range of antiepileptic targets for CBDV. He wanted to see if there could be effects on the g-aminobutyric acid (GABA) A receptors. GABAergic neurons play an essential function in the control of epileptic centers. Morano found that prolonged use of CBDV decreases the GABA dependent currents in the brain. He ascertained those using cannabis with partial epilepsy had a decrease in seizure frequency. In addition, there was an improvement in cognitive functionality. This is a possible parallel with high concentrations of CBDV.
For people with epilepsy, this is substantial news, as there is not only a reduction in seizure frequency and effects but also an improvement in cognitive function.
Advances in Chronic Nausea and CBDV
CBDV reduces or eliminates nausea associated with several conditions, and helps to reduce inflammation throughout the body. CBDV is also beneficial in the treatment of pain and mood disorders.
In 2013, Rock tested THCV and CBDV for their ability to induce nausea through the cannabinoid-1 (CB1) receptor. The CB1 receptors are present in very high concentrations in the brain and in lower amounts spread throughout the body. These receptors mediate the psychoactive effects of cannabinoids. Rock determined through the study design that mice tested were not experiencing induced nausea with either THCV or CBDV. In fact, data obtained shows a reduced effect, with CBDV being the weakest cause of nausea.
For anyone not responding to conventional treatments for nausea or inflammation, CBDV may be a viable treatment option.
Emerging Science for Bone Marrow Formation
In 2007, Scutt and Wiliamson discovered that CB1 and CB2 receptors are involved in bone marrow formation. To prove their finding the CBDV and other natural cannabinoids were tested in a fibroblastic colony-forming units. All cannabinoids were successful in producing the colony formations. The result varied from a small stimulation of about 20 percent up to 100 percent under CBDV treatment.
Targeted CBDV in NeuroScience: Autism Spectrum Disorder
In 2018, a Phase 2a placebo-controlled study was formed. This evaluated the efficacy and safety of GWP42006 (GW), which features CBDV as the primary cannabinoid molecule. It displayed a reduction in focal seizures by approximately 40 percent of those tested.
GW also did a study of both general and syndromic preclinical models of Autism Spectrum Disorder (ASD). There were promising signs of cognitive and social endpoints including, repetitive behavior. Included in this are determined abnormalities of neurobehavioral and chemically induced models, which includes Rett syndrome and Fragile X plus more.
Rett syndrome is a neurological disorder that is more apparent in girls than boys are during the infancy. Fragile X is a genetic condition that affects the development of children comprised of learning disabilities and cognitive impairment. Seizures will occur more often in males than in females.
Additionally, Montefiore Medical Center at the Albert Einstein College of Medicine received a $1.3m grant to fund ongoing research of the cannabinoid Cannabidivarin and ASD. Previous investigative teams generated optimistic outcomes in calming anxiety, violent episodes, and seizures in autistic children.
As more is learned about ASD, scientists can further develop effective action plans and research design.
Lights of Hope
Science perpetually furthers our collective knowledge. Smoking cannabis is a controversial unpredictable solution to acquire CBD medicinal benefits, with erratic blood levels and therapeutic effect. People risk becoming dependent on the mind-altering effects and feeling out of control while desperately seeking medical relief.
Extracting cannabidivarin from the psychoactive Cannabis and creating a pure, standardized and validated CBDV agent opens up expanding hope and support for individuals with conditions or circumstances unresponsive or unreceptive to conventional care.
The Federal Food, Drug, and Cosmetic Act requires that we inform you that the efficacy of CBD or CBDV products has not been confirmed by FDA-approved research as a treatment for any medical condition. The information in this document is not intended to diagnose, treat, cure or prevent any disease.